NO20024352L - Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner - Google Patents

Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner

Info

Publication number
NO20024352L
NO20024352L NO20024352A NO20024352A NO20024352L NO 20024352 L NO20024352 L NO 20024352L NO 20024352 A NO20024352 A NO 20024352A NO 20024352 A NO20024352 A NO 20024352A NO 20024352 L NO20024352 L NO 20024352L
Authority
NO
Norway
Prior art keywords
dihydroisobenzofurans
fluorophenyl
substituted
stepwise alkylation
alkylation
Prior art date
Application number
NO20024352A
Other languages
English (en)
Other versions
NO20024352D0 (no
Inventor
Hans Petersen
Haleh Ahmadian
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20024352D0 publication Critical patent/NO20024352D0/no
Publication of NO20024352L publication Critical patent/NO20024352L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
NO20024352A 2000-03-13 2002-09-12 Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner NO20024352L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000403 2000-03-13
DKPA200000414 2000-03-14
PCT/DK2001/000159 WO2001068629A1 (en) 2000-03-13 2001-03-09 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans

Publications (2)

Publication Number Publication Date
NO20024352D0 NO20024352D0 (no) 2002-09-12
NO20024352L true NO20024352L (no) 2002-10-08

Family

ID=26068792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024352A NO20024352L (no) 2000-03-13 2002-09-12 Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner

Country Status (22)

Country Link
US (2) US6864379B2 (no)
EP (1) EP1265881A1 (no)
JP (1) JP2003527385A (no)
KR (1) KR20020080485A (no)
CN (1) CN1427835A (no)
AU (1) AU2001239210A1 (no)
BG (1) BG107046A (no)
BR (1) BR0109364A (no)
CA (1) CA2402553A1 (no)
CZ (1) CZ20023100A3 (no)
EA (1) EA200200968A1 (no)
HR (1) HRP20020758A2 (no)
HU (1) HUP0300273A2 (no)
IL (1) IL151566A0 (no)
IS (1) IS6530A (no)
MX (1) MXPA02008684A (no)
NO (1) NO20024352L (no)
NZ (1) NZ521204A (no)
PL (1) PL357022A1 (no)
SK (1) SK14522002A3 (no)
TR (1) TR200202195T2 (no)
WO (1) WO2001068629A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE237604T1 (de) 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
IES20010157A2 (en) 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
EP1446396A1 (en) * 2001-11-08 2004-08-18 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
PE20040991A1 (es) 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
EP1706394B1 (en) * 2003-11-12 2014-12-17 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
TWI339651B (en) 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
CA2967430C (en) * 2005-03-10 2018-05-08 Gen-Probe Incorporated Systems and methods to perform assays for detecting or quantifying analytes within samples

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (no) 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DE19626659A1 (de) 1996-07-03 1998-01-08 Basf Ag Verfahren zur Herstellung von Phthaliden
DE19627697A1 (de) 1996-07-10 1998-01-15 Basf Ag Verfahren zur Herstellung von Phthaliden
PT1015416E (pt) 1997-07-08 2002-03-28 Lundbeck & Co As H Metodo para a producao de citalopram
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
CA2291072C (en) 1997-11-11 2002-08-20 H. Lundbeck A/S Method for the preparation of citalopram
HU228576B1 (en) 1998-10-20 2013-04-29 Lundbeck & Co As H Method for the preparation of citalopram
AU764161B2 (en) 1998-12-23 2003-08-14 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
ATE237604T1 (de) 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
ITMI991581A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
SK287139B6 (sk) 1999-10-25 2010-01-07 H. Lundbeck A/S Spôsob prípravy citalopramu
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) * 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
WO2001047909A1 (en) * 1999-12-28 2001-07-05 H. Lundbeck A/S Method for the preparation of citalopram
UA73336C2 (en) 1999-12-30 2005-07-15 Lundbeck & Co As H A method for the preparation of 5-cyano-phtalid
TR200201783T2 (tr) 2000-01-14 2002-12-23 H. Lundbeck A/S 5-Siyanofatalid hazırlamak için yöntem
IT1317729B1 (it) 2000-01-18 2003-07-15 Norpharma S P A Procedimento per la preparazione della 5-carbossiftalide.
US6433196B1 (en) 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
IES20010143A2 (en) 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
NL1017415C1 (nl) 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
IES20010157A2 (en) 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
IL151490A0 (en) * 2000-03-13 2003-04-10 Lundbeck & Co As H Method for the preparation of citalopram
KR20020080476A (ko) * 2000-03-14 2002-10-23 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
EP1274699A1 (en) 2000-03-16 2003-01-15 H. Lundbeck A/S Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
SK3362002A3 (en) 2000-07-06 2002-08-06 Lundbeck & Co As H Method for the preparation of citalopram
FI20011622A (fi) 2000-08-18 2002-02-19 Lundbeck & Co As H Menetelmä sitalopraamin valmistamiseksi
EA003581B1 (ru) 2000-12-22 2003-06-26 Х.Лундбекк А/С Способ получения чистого циталопрама
AU3920201A (en) 2000-12-28 2001-07-09 H. Lundbeck A/S Process for the preparation of pure citalopram

Also Published As

Publication number Publication date
MXPA02008684A (es) 2003-02-24
TR200202195T2 (tr) 2002-12-23
HRP20020758A2 (en) 2004-12-31
EP1265881A1 (en) 2002-12-18
CA2402553A1 (en) 2001-09-20
SK14522002A3 (sk) 2003-03-04
BG107046A (en) 2003-05-30
AU2001239210A1 (en) 2001-09-24
CN1427835A (zh) 2003-07-02
BR0109364A (pt) 2002-12-24
US6864379B2 (en) 2005-03-08
WO2001068629A1 (en) 2001-09-20
CZ20023100A3 (cs) 2003-02-12
US20050020670A1 (en) 2005-01-27
IS6530A (is) 2002-08-27
IL151566A0 (en) 2003-04-10
NO20024352D0 (no) 2002-09-12
EA200200968A1 (ru) 2003-02-27
US20030083509A1 (en) 2003-05-01
JP2003527385A (ja) 2003-09-16
PL357022A1 (en) 2004-07-12
KR20020080485A (ko) 2002-10-23
HUP0300273A2 (hu) 2003-06-28
NZ521204A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
NO20041075L (no) Ny 1, 2, 4-triazolforbindelse
IS6913A (is) 3-(4-amídópýrról-2-ýlmetlíden)-2-indólínon afleiður sem prótein kínasa hindrar
ID30460A (id) Inhibitor-inhibitor protein siklik tirosin kinase
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
EE05386B1 (et) Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
DE60128709D1 (de) Triazol-verbindungen als protein-kinase-inhibitoren
NO20034930L (no) Substituerte cykloheksan-1,4-diaminderivater
NO20024742L (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20014987D0 (no) Substituerte azoler
NO20022095D0 (no) Heterocyklisk substituerte pyrazoloner
NO326461B1 (no) Rommersko
BR9915534B1 (pt) 1-piridil substituìdo)-1,2,4-triazóis inseticidas.
NO20024352D0 (no) Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner
NO20024197L (no) Fremgangsmåte ved fremstilling av 5-cyano-1-(4-fluorfenyl)- 1,3-dihydroisobenzofuraner
DE60202489D1 (de) Lysin enthaltende kautablette
DE60043733D1 (de) Paketauthentifizierung
DE60231897D1 (de) Triazol derivate als cyclooxygenase inhibitoren
DE60024233D1 (de) Verwendung kationischer Verbindungen
DE69900626D1 (de) Abgleichbare, frequenzstabilisierende, chipinterne kondensatoranordnung
DE29903011U1 (de) Einbauspüle
AR027974A1 (es) 1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
NO20015564L (no) Imidazo-inneholdende heterocykliske forbindelser, deres sammensetninger og anvendelser
ATE360010T1 (de) Heterocyclische retioidverbindungen
ES1052668Y (es) Proteccion segura.
ITRM20000607A1 (it) Protezione monouso per lavandini.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application